Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This doesn't appear to be a merger in any form so IMMB shareholders just keep their shares. It looks like ECPO claims to be a holding company of majority of the IMMB shares and hence calls IMMB a subsidiary and NOT a wholly owned subsidiary. Currently, broker-dealers are prohibited from soliciting investors to buy or sell IMMB stock until certain reporting requirements are met.
You should ask the company.
IR Contact:
Immunotech Laboratories, Inc.
120 W Pomona Ave
Monrovia, CA 91016
Phone: (626) 538-4779
Fax: (626) 538-4779
harry@immunotechlab.com
I would be very surprised if the acquisition makes it through the entire process (similar to BSSP). IMM* was severely tainted by attorney Adam S. Tracy (Securities Compliance Group, Ltd.) who got banned within a week of this mergers announcement. Should be interesting to watch.
https://www.otcmarkets.com/research/service-provider/Securities-Compliance-Group-Ltd.?id=4847&b=n&filterOn=3
More about Adam
On March 9, 2017, the Company (ECPO) entered into an agreement with the shareholders of Immunotech Laboratories, Inc. (Immunotech) to acquire all of the outstanding shares, both preferred and common stock, of Immunotech for 60,000,000 shares of the Company’s Series A preferred stock. The current shareholders of Immunotech ownership, not less than 80% of the issued and outstanding shares of ECPO common stock at any given time. At the effective time of the Acquisition, all options to acquire common stock of Immunotech issued and outstanding, whether vested or unvested, shall automatically be converted into and become options to purchase shares of Common Stock. Immunotech’s 200 Million outstanding Series B Preferred convert one to one but do have a voting preference and shall be exchanged for 200 Million Series B Preferred shares of ECPO with the exact same voting preferences as the Immunotech Series B Preferred. The Series B outstanding will be included in the 80% calculation for the Newly Created Preferred.
================================
All this and no 8K?
Looks like Harry just bought a new ticker:
https://www.otcmarkets.com/stock/ECPO/profile
Thanks Bro. These guys burn tickers like marshmallows at a cub scout bon fire.
Market opens with BSSP at a new 52 week high this morning.
I believe there is enough for a civil suit against EFIR. I also believe the Form 15G filed was incorrect and a means to hide info from regulators and shareholders.
This can't be right->
Approximate number of holders of record as of the certification or notice date: 338
People that held 5 million shares or less before August 2008 were reverse split to 1 share.
Security Notes
•Capital Change=shs decreased by 1 for 200 split Pay date=10/08/2008.
•Capital Change=shs decreased by 1 for 50 split Pay date=11/09/2010.
•Capital Change=shs decreased by 1 for 500 split. Pay date=07/07/2011.
Certainly BSSP put in a news release but it was rejected.
Applied for name/ticker change REJECTED
License to operate in Mexico REJECTED
Buy orders for BSSP common shares REJECTED
Next week, they can say "News in 7 to 10 days". That seems to be the pattern anyways. Personally, I think every day they don't file their SEC documents should be news enough for most folks. BSSP is dead until they become current with SEC filings.
Yeah the rest of us confirmed that over a year ago.
On April 19, 2016, in behalf of the Registrants Purchase Agreement with Canteck Pharma, Inc. Mrs. Diana Zhabilov was appointed as Chairman and President of the Registrant, and Mr. Harry Zhabilov was appointed as Chief Science Officer and Treasurer of the Registrant. Mr. Dennis Alexander shall serve as Chief Executive Officer and Director, and Ms. Joanne Sylvanus as Chief Financial Officer, Secretary and Director. Mr. Alexander will receive a salary of Five Thousand Dollars ($5,000) per month and Ms. Slyvanus, Three Thousand Dollars ($3,000) per month.
Even if one were to buy $10,000 of MNVN the money would go to another shareholder. The company can not sell shares directly to the public but only to qualified investors or conversions of notes. So if someone really wanted to bail out the company, they would have to mail a check to Dennis as a gift or loan instead of buying shares.
He will need about $80,000. The company isn't worth that much since the only thing they own is common stock in Boomerang Oil which is defunct. He may just give you the whole company for nothing if you agree to assume liabilities.
It is just done to correct the annual which was filed the day before. Look at the history at Wyoming S.O.S. and you will see the correction and original.
No. Looks like they are just correcting the president title in Wyoming.
Some brokers will not sell this ticker as noted by PistolPete who tried to load the boat on last weeks news. I assume there is a clearing problem with the stock which puts a chill on trading BSSP. Lot's of problems with this ticker.
Yeah I know how this plays out. Even the most optimistic view is very bleak for BSSP as a company. I also know that Dennis' socks, underwear and the steak he will eat tonight were paid for with investors money. I don't expect he will give up on a paycheck. Dennis has raised millions on behalf of several companies yet none of them have a penny in the bank but instead are saddled with debt. I don't think he is done milking this cow. If he can ever get the CUSIP/Ticker change, there will be nothing stopping a toxic lender frenzy and dump. Certainly there must be some greedy auditors and lawyers out there that can produce fake financials. They used to be a dime a dozen but penalties got stiffer in recent years. Dennis had used M&K CPAS in the past but I think they are still banned after Microcap Fraud findings.
The press release was pretty telling.
Recent attempt for permit failed.
LOI to use ZELOR SAPI manufacturing facility failed.
Potential investors have to ask how long does it take to:
1) Construct a medical manufacturing building and acquire zoning and permits for such activity.
2) Develop a completely new compound which contains at least one substance that has been previously prohibited by regulators.
3) Complete all phases of clinical trials and then get regulator approval for a new medical treatment.
Assuming all goes as advertised and funding is adequate; 10 years.
Auth Shares are unlimited and Harry's shares have a non-dilutable designation so why not keep selling at .0001? OS could go to 100 billion with no ill effect on ownership and control. For every new share issued, Harry gets one in order to retain his 60%. The only reason to get pps up may be to uplist to NYSE,AMEX or perhaps attract institutional investors. Without becoming current, no corporate actions will be approved by FINRA, however.
Minimally a joint statement from the other party. I have never seen Dr. Hector Zepeda Lopez acknowledge an association with Harry although Harry has dropped the doctors name several times during the past 10 years.
Not so fast. Nothing has been done except an understanding over some beers in Tijuana. Absence of an 8K indicates this is NOT a material event. TCM is not an entity but an acronym for Modulator T cells.
Do you have any idea how many times Harry has done this exact same thing with investors? Read this carefully then go find your answer:
http://www.onlineformpressrelease.com/2013193548/Immunotech-Laboratories-Clinical-Trial-Announcement/news.html
In actuality, the deal we are referring to was brokered by a third company, Global Media Network USA, INC. owned by Dennis Alexander.
So Dennis and Dennis got together and decided to hire Dennis as a consultant to make the deal. It has to be the most "in your face" abuse of fiduciary duty I have ever seen.
I can recall only one LOI that Dennis did that ever came to fruition but Dennis was/is CEO of both of the companies that made the deal. Today's MOU is nothing but kicking the can down the road.
It looks like BSSP's application was rejected again so they gave up on their drug and want to make a new one. Maybe in 5-10 years....
****NEWS****
Cantech Holding, Inc. (BSSP) Announces Execution of Memorandum of Understanding With the TCM Group for the Creation of a Joint Venture and Development of a New Compound for Inclusion in the Doctor at Home Program in Mexico
MONROVIA, CA -- (Marketwired) -- 05/10/17 -- Cantech Holding, Inc., formerly Reve Technologies, Inc., (OTC PINK: BSSP) (the "Company" or "Cantech") a development stage immunotherapeutic based technology company today announced it has executed a Memorandum of Understanding (the "MOU") between TCM Group ("TCM") and Cantech Intl. Group Mexico ("CIGM"), a to be newly formed unit of Cantech Holding, Inc. for the construction of a manufacturing facility in the city of Tijuana B.C. Mexico. Updating the previously reported August 19, 2016 announcement, and based on several months of discussion and developments the resulting new collaborative joint venture now directly between the principle scientists entities proposes i) TCM will manufacture the specific compound T Cell Modulator and ii) CIGM will manufacture the specific compound Irreversible Pepsin Fraction to be marketed and sold as a newly combined treatment as well as for individual compound applications. All products require authorization to manufacture and sale under the health and sanitary legal framework of Mexico.
Dr. Hector Zepeda Lopez on behalf of TCM, and Harry Zhabilov, CSO of Cantech Holding and on behalf of CIGM will endeavor to form a new compound from the combination of the two existing treatments, T Cell Modulator and the Irreversible Pepsin Fraction to become a registered medicine as part of the application with COFEPRIS for approval and integration into the current Human Studies of the T Cell Modulator to fast track the approval process.
The primary focus of the new compound will be for inclusion in the Health Department of Mexico City "Doctor at Home Program" which has indicated the potential acceptance of Dr. Zepeda's treatment protocol. The "Doctor at Home Program" has been very successful and it is now being franchised to other government health organizations in central and South American countries. Through the joint venture the new compound would be produced for commercial sales nationwide in the United Mexican States and in other Latin American countries participating in the Doctor at Home Program spearheaded by Mexico.
About Canteck Pharma, Inc. IPF for Cancer treatment
Immunotherapy has the potential to provide an alternative and/or complementary treatment in combination with other immune base therapy for several types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.
Unfortunately the immune system by itself can't recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.
IPF proteins attach to tumor antigens, creating super-antigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.
It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.
This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent -- fraction and/or its proteins that can attach, serve as the immunogen are already known.
About Cantech Holding, Inc. (f/k/a Reve Technologies, Inc.)
www.cantechholding.com
The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company's Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico. The Company changed its name to Cantech Holding, Inc. effective on May 27, 2016 and its domicile to Wyoming from Nevada also effective on May 27, 2016.
About TCM, the TCM Group, Dr. Hector Zepeda Lopez Ph. D. and Mario Rodriguez Ph.D.
The collaboration and association with TCM merits a description of the principal members of the TCM group, starting with Dr. Zepeda Lopez holder of the Influenza virus H1N1 vaccine patent and developed for the 2009 pandemic outbreak in Mexico, Dr. Zepeda holds 6 Ph.Ds. and has had post-doctoral stays at Sick Children Hospital, Microbiology Section Toronto Canada,Health Science Center Molecular Biology Dept. Texas University USA, Karolinska Institute Molecular Diagnostic Dept. Stockholm Sweden, Pasteur Institute Molecular Pathogenesis Dept. Paris France and the Center of Development Vaccine Baltimore USA 1997. Also integrating the TCM group is Mario Rodriguez Ph.D. and scientist and engineer with vast experience in physic, electronic, optical technologies, state of the technology set up and manufacturing, with degrees from San Diego State University and the University of California Irvine, as well as a Ph.D. from the Imperial College in London. Mario currently participates directing the manufacturing efforts of highly specialized defense systems for several contractors, his expertise in GMP and highly specialized and regulated facilities setup and organization is of the most important usefulness in this endeavor.
TCM is capable of modulating the immune response through activation of specific molecules involved in controlling innate immunity termed "toll like receptors". Clinical data has been generated in a variety of immunologically-associated conditions including multiple sclerosis, viral infections, and cancer. In vitro data demonstrates consistent production of immune modulatory cytokines including interferons and interleukins after treatment of immune cells with TCM.
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Cantech Holding, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Cantech Holding, Inc.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Cantech Holding, Inc.'s filings with the Securities and Exchange Commission.
CONTACT INFORMATION Public Relations and Shareholder Information
Name:
Dennis Alexander
CEO
Phone: (602) 326-7371
Email: info@cantechholding.com
Source: Cantech Holding, Inc.
https://www.otcmarkets.com/news/otc-market-headline?id=792737
I had to laugh at several points in the video. They actually make a claim that they can "cure" cancer yet no major (legitimate) company is interested in active talks with them. They point this out actually.
I think February 2017.
http://www.microsofttranslator.com/bv.aspx?from=bg&to=en&a=http%3A%2F%2Fwww.immunotechlaboratoriesbg.com%2Finterviews
Cantech resubmitted Biologic License Application in Mexico on April 24, 2017. The application is listed as active but it appears to be incomplete. Not expecting much here.
****NEWS****
And here is the new pump:
http://s.vid.ly/embeded.html?link=d3e7p2&autoplay=false
I just got filled at 11.21 with my fingers crossed to go north of 12. But it seem to be bottomless at the moment.
Looks like $12 to me with a cautious upward target depending on the Naples release and adoption. I think AMD has a great future if they can execute their plan. Currently I am out of AMD but am looking for another entry point.
If earning are better than neg .03 then AMD will rocket.
Last estimate I seen was a -$0.04 but I am expecting a -$0.07 given all the new things that were developed but do not have revenue yet. Q2 should be a great recovery with Q3 through year end very profitable for AMD. The key would be to get Naples into datacenters by the end of May. I can see Amazon embracing Naples.
I expect a significant drop in pps on Monday.
The company already said they can't get money from the toxic lenders until they get name/ticker change. They can't get name/ticker change until they are current with filings. They can't get current with filing until they get money for auditors and lawyers. They can't issue unregistered shares to the public. They can't sell product due to troubles with Mexican regulators.
There is nothing to pump so the company is behaving as expected. You suggest they make stuff up? LOL
The 100 daily MA is making impact solidly on .0001 this week and we have a technical trader making a play all week long because of this phenomenon. Can you not do the same thing he is doing then go buy a yacht? Seems simple enough to me.
...Trying to calculate half of unlimited but it seems I don't have an infinity key on my calculator. Just trying to figure the real potential here.
About the only thing you can bet on would be that BSSP will arrive at a new 52 week high on June 8, 2017.
It appears that BSSP missed another filing deadline yesterday which now equates to at least ten of its required filings with the SEC. Will the company even renew its business license in Wyoming next month? Typical of a Alexander grab and run operation. Pretty sure he is already milking another cow by now.